Bavarian Nordic (CPSE:BAVA) - Cotización, noticias y análisis

Resumen de acción BAVA

Bavarian Nordic A/S desarrolla, fabrica y comercializa vacunas que salvan vidas.

BAVA fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 92.6% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 5.24%

Los beneficios aumentaron un 227.1% el pasado año

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Grandes partidas extraordinarias que afectan a los resultados financieros

Competidores de Bavarian Nordic A/S

Genmab

CPSE:GMAB

kr.129.4b

ChemoMetec

CPSE:CHEMM

kr.5.4b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$1.8b

PeptiDream

TSE:4587

JP¥254.3b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Bavarian Nordic
Historical stock prices
Current Share Price	kr.162.90
52 Week High	kr.222.00
52 Week Low	kr.125.55
Beta	1.33
1 Month Change	7.42%
3 Month Change	4.12%
1 Year Change	-21.98%
3 Year Change	-37.35%
5 Year Change	19.82%
Change since IPO	-36.12%

Noticias y actualizaciones recientes

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09

Recent updates

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Feb 26

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Jan 03

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Dec 10

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Nov 15

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Aug 17

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 19

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Jan 03

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Sep 15

Rainbows and Unicorns: Bavarian Nordic A/S (CPH:BAVA) Analysts Just Became A Lot More Optimistic

Jul 24

Industry Analysts Just Made A Notable Upgrade To Their Bavarian Nordic A/S (CPH:BAVA) Revenue Forecasts

Jun 14

Analyst Forecasts Just Became More Bearish On Bavarian Nordic A/S (CPH:BAVA)

May 31

Is Bavarian Nordic (CPH:BAVA) Using Debt In A Risky Way?

May 06

Bavarian Nordic A/S (CPH:BAVA) Analysts Just Cut Their EPS Forecasts Substantially

Mar 13

Rentabilidad de los accionistas

	BAVA	DK Biotechs	Mercado DK
7D	4.7%	-0.5%	3.2%
1Y	-22.0%	-15.9%	22.7%

Rentabilidad vs. Industria: Los resultados de BAVA fueron inferiores a los de la industria Danish Biotechs, que obtuvo un rendimiento del -10% el año pasado.

Rentabilidad vs. Mercado: BAVA obtuvo unos resultados inferiores a los del mercado Danish, que fue del 26.5% el año pasado.

Volatilidad de los precios

Is BAVA's price volatile compared to industry and market?
BAVA volatility
BAVA Average Weekly Movement	5.7%
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.6%
10% most volatile stocks in DK Market	9.9%
10% least volatile stocks in DK Market	2.8%

Precio estable de las acciones: BAVA no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BAVA (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1992	1,379	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S desarrolla, fabrica y comercializa vacunas que salvan vidas. La empresa ofrece vacunas no replicantes contra la viruela y la viruela del mono con los nombres IMVAMUNE, IMVANEX y JYNNEOS; vacuna antirrábica para uso humano con el nombre Rabipur/RabAvert; vacuna contra la encefalitis transmitida por garrapatas con el nombre Encepur; y vacuna contra el ébola con el nombre MVABEA. También está desarrollando MVA-BN para el tratamiento de la viruela; MVA-BN RSV, que se encuentra en ensayos clínicos de fase III para el tratamiento del virus respiratorio sincitial; ABNCoV2 que ha completado el ensayo clínico de fase III para el tratamiento del SARS-CoV-2.

Resumen de fundamentos de Bavarian Nordic A/S

¿Cómo se comparan los beneficios e ingresos de Bavarian Nordic con su capitalización de mercado?
Estadísticas fundamentales de BAVA
Capitalización bursátil	kr.12.70b
Beneficios(TTM)	kr.984.37m
Ingresos (TTM)	kr.6.64b

12.9x

Ratio precio-beneficio (PE)

1.9x

Ratio precio-ventas (PS)

¿Está BAVA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BAVA
Ingresos	kr.6.64b
Coste de los ingresos	kr.2.04b
Beneficio bruto	kr.4.60b
Otros gastos	kr.3.62b
Beneficios	kr.984.37m

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

Aug 22, 2024

Beneficios por acción (BPA)	12.63
Margen bruto	69.29%
Margen de beneficio neto	14.82%
Ratio deuda/patrimonio	0.2%

¿Cómo se ha desempeñado BAVA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción BAVA

Recompensas

Análisis de riesgos

Competidores de Bavarian Nordic A/S

CPSE:GMAB

kr.129.4b

CPSE:CHEMM

kr.5.4b

NasdaqCM:CPRX

US$1.8b

TSE:4587

JP¥254.3b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Deputy Chairman exercised options to buy kr.123k worth of stock.

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Recent updates

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Deputy Chairman exercised options to buy kr.123k worth of stock.

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

CEO & President exercised options to buy kr.1.4m worth of stock.

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Price target increased by 9.4% to kr.293

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Consensus EPS estimates increase by 40%

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to kr.418

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Consensus forecasts updated

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Price target increased to kr.390

Rainbows and Unicorns: Bavarian Nordic A/S (CPH:BAVA) Analysts Just Became A Lot More Optimistic

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Consensus estimates of losses per share improve by 21%

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022